Dane Leone

Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In

Why This Ayala Pharmaceuticals Analyst Is Bullish

Sell-Side Remains Optimistic On Sage Therapeutics Despite Depression Drug Disappointment

Why This Ayala Pharmaceuticals Analyst Is Bullish

Sell-Side Remains Optimistic On Sage Therapeutics Despite Depression Drug Disappointment

Raymond James Downgrades Ocular Therapeutix, Remains Bullish On Pipeline

Bluebird Bio's Competitive Advantage Is Underappreciated, Raymond James Says In Bullish Initiation

Raymond James Downgrades Ocular Therapeutix, Remains Bullish On Pipeline

Bluebird Bio's Competitive Advantage Is Underappreciated, Raymond James Says In Bullish Initiation

G1 Therapeutics Investors Recoil, Analysts Bullish In Wake Of Trilaciclib Results

Raymond Sees Billion $1B Potential In Loxo Oncology's Vitrakvi, LOXO-95

Dane Leone Recent News

3 Reasons To Like Vertex Pharma Shares

Johnson & Johnson Shares Might Break Lower Before They Break Out

This Analyst Is Disappointed With Performance Of Celgene's Mongersen, Ozanimod

After Bluebird's 75% Gain In 2017, Analysts At BTIG Downgrade To Neutral

Here's The Beef With Bluebird's Starbeam Study Results

The Only Bullish Scenario For Juno Therapeutics: Its CEO May Get Fired

Key Reasons BTIG Just Upgraded Kite Pharma

Nesvacumab Key Catalyst For Regeneron In 2017; BTIG Upgrades To Buy

Juno Therapeutics' Hold Is 'More Impactful To Sentiment Than Estimates'

BTIG Is No Longer Selling Juno Therapeutics Stock

Favorable FDA Pathway Should Keep Bluebird's Clinical Studies Flying Straight

Illumina's Poor Streak Is A Sign Of Market Saturation

Sell Juno Therapeutics: BTIG Says It's Trailing The Competition

BTIG Is 'Generally Skeptical' On Kite Pharma Expectations

BTIG Research Upgrades Alere To Buy, Says 10-K Filing Offers 'Fundamental Opportunity'

Celgene Could Achieve 2020 Targets, BTIG Upgrades To Buy

Celgene Downgraded To Netural As Company Might Be Relying Too Heavily On Revlimid

Under-Promising, Over-Delivering: Has Agilent's Management Gained Credibility?

BTIG Comments On Bluebird Bio's Q1 Print, Highlights Future Catalysts

BTIG Downgrades Bruker, Still Likes Long-Term Story

BTIG Starts MacroGenics At Buy, Sees 63% Upside

UPDATE: BTIG Initiates Coverage On Thermo Fisher Scientific Inc.

UPDATE: BTIG Initiates Coverage On Affymetrix, Inc.